|
Mr. Zisson is a partner of Thomas, McNerney & Partners. He joined Thomas, McNerney in 2002 and is currently a board member of Clarus Therapeutics, Inc., Tranzyme Pharma, Inc. and Zogenix, Inc. Before joining the firm, he spent eleven years in the research department at Hambrecht & Quist (and its successor firms Chase H&Q and JPMorgan H&Q). During his tenure at H&Q, Mr. Zisson led research teams covering the biotechnology, specialty pharmaceutical, large-cap pharmaceutical, drug delivery and diagnostic industries. After the merger of Chase H&Q and JPMorgan, he became the firm�s Health Care Strategist. Mr. Zisson was named twice in The Wall Street Journal�s All-Star Analysts Survey, including during his last year at JPMorgan when he placed in all three categories: stock picking (#1 in pharmaceuticals), earnings estimate accuracy (tied for #2), and �home run� hitting (#8 across all industries). He graduated magna cum laude from Brown University, where he was elected to Phi Beta Kappa. | 